Hepatocellular carcinoma in 2017: Two large steps forward, one small step back

Hepatocellular carcinoma in 2017: Two large steps forward, one small step back, Published online: 04 January 2018; doi:10.1038/nrgastro.2017.174

In 2017, the FDA approved regorafenib and nivolumab for the treatment of patients with hepatocellular carcinoma following prior sorafenib treatment, opening the door for an effective systemic second-line therapy in advanced disease. By contrast, the addition of sorafenib to transarterial chemoembolization with drug-eluting beads did not improve progression-free survival in the intermediate disease stage.

中文翻译：

---

2017年肝细胞癌：向前迈出了两大步，向后迈出了一小步

2017年肝细胞癌：向前迈出了两大步，向后迈出了一小步

2017年肝细胞癌：向前迈出了两大步，向后迈出了一小步，在线发布：2018年1月4日; doi：10.1038 / nrgastro.2017.174

2017年，FDA批准了regorafenib和nivolumab用于先前索拉非尼治疗后的肝细胞癌患者的治疗，为晚期疾病的有效全身性二线治疗打开了大门。相比之下，将索拉非尼与药物洗脱珠一起添加到经动脉化学栓塞中并不能改善疾病中期阶段的无进展生存期。